- Thinly traded nano cap Trovagene (TROV +5%) perks up in early trading, albeit on turnover of only 12K shares, after the company announced results from a Phase 1 safety study of blood cancer candidate PCM-075, recently licensed from Italian firm Nerviano Medical Sciences.
- PCM-075 was administered once daily for five consecutive days in 21 patients with confirmed metastatic disease, most with solid tumors instead of blood cancer.
- The most common dose-limiting toxicities were thrombocytopenia (low blood platelets) and neutropenia (low level of white blood cells called neutrophils), which was expected due to PCM-075's inhibition of polo-like kinase 1 (PLK1). The toxicities were reversible. One patient experienced grade 3 (serious) constipation which may have been due to the concomitant treatment with opioids.
- The company plans to launch a Phase 1/2 study in acute myeloid leukemia (AML).
- Previously: Trovagene nabs rights to leukemia candidate from Nerviano Medical (March 15)
- Now read: Puma Pulls Within Sight Of FDA OK
Original article